Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CISD1 | Q9NZ45 | 11/20 | 0.60 |
| ▸ | CA12 | O43570 | 4/20 | 0.60 |
| ▸ | CA1 | P00915 | 4/20 | 0.60 |
| ▸ | CA2 | P00918 | 4/20 | 0.60 |
| ▸ | CA9 | Q16790 | 4/20 | 0.60 |
| ▸ | CA4 | P22748 | 3/20 | 0.60 |
| ▸ | CA6 | P23280 | 3/20 | 0.60 |
| ▸ | CA7 | P43166 | 3/20 | 0.60 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.60 |
| ▸ | CA5B | Q9Y2D0 | 3/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | CA5A | P35218 | 2/20 | 0.60 |
| ▸ | HTR1A | P08908 | 1/20 | 0.60 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.60 |
| ▸ | SLC10A1 | Q14973 | 1/20 | 0.60 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.60 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14399052 | 0.90 | CISD1 (0.58) | CISD1CA12CA1CA2CA9 | |
| SCHEMBL10108681 | 0.85 | CISD1 (0.60) | CISD1CA12CA1CA2CA9 | |
| SCHEMBL4944715 | 0.76 | CA12 (0.56) | CISD1CA12CA1CA2CA9 | |
| Furosemide SCHEMBL27537915 | 0.76 | CISD1 (0.92) | CISD1CA12CA1CA2CA9 | |
| SCHEMBL11008942 | 0.76 | CISD1 (0.60) | CISD1CA12CA1CA2CA9 | |
| Furosemide SCHEMBL428921 | 0.75 | CISD1 (1.00) | CISD1CA12CA1CA2CA9 | |
| Furosemide SCHEMBL29406913 | 0.75 | CISD1 (1.00) | CISD1CA12CA1CA2CA9 | |
| Furosemide SCHEMBL9811 | 0.75 | CISD1 (1.00) | CISD1CA12CA1CA2CA9 | |
| SCHEMBL2879988 | 0.75 | CISD1 (0.59) | CISD1CA12CA1CA2CA9 | |
| SCHEMBL1741237 | 0.74 | CA1 (0.52) | CISD1CA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8101782-B2 | Drug hybrid of rivastigmine or physostigmine with tranylcypromine, amoxapine, desipramine, nortriptyline, protriptyline, fluoxetine, fluvoxamine, paroxetine, duloxetine, betahistine, amlodipine, proylhexedrine, rimantadine, desloratadine; Alzheimer's disease; Parkinson's disease, impairment in memory | COLUCID PHARMACEUTICALS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-20080261950-A1 | Compounds that inhibit cholinesterase | COLUCID PHARMACEUTICALS, INC. (US) | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261950-A1 | Compounds that inhibit cholinesterase | ACHE, BCHE, CHAT | CISD1 3957/4885CA12 649/4885CA1 219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.